Agenus advances cancer drug combo to phase 3, reports early revenue

March 16, 2026 7:30 AM

Agenus Inc. (NASDAQ: AGEN) reported that its experimental cancer drug combination botensilimab plus balstilimab has advanced to a phase 3 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found